PureTech Net Income From Continuing Ops from 2010 to 2026
| PRTC Stock | USD 18.69 0.42 2.20% |
Net Income From Continuing Ops | First Reported 2010-12-31 | Previous Quarter 31.9 M | Current Value 33.5 M | Quarterly Volatility 109.9 M |
Check PureTech Health financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among PureTech Health's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.9 M, Interest Expense of 6.7 M or Selling General Administrative of 27.2 M, as well as many indicators such as Price To Sales Ratio of 88.15, Dividend Yield of 2.0E-4 or PTB Ratio of 1.13. PureTech financial statements analysis is a perfect complement when working with PureTech Health Valuation or Volatility modules.
PureTech | Net Income From Continuing Ops | Build AI portfolio with PureTech Stock |
Analyzing PureTech Health's Net Income From Continuing Ops over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income From Continuing Ops has evolved provides context for assessing PureTech Health's current valuation and future prospects.
Latest PureTech Health's Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of PureTech Health PLC over the last few years. It is PureTech Health's Net Income From Continuing Ops historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in PureTech Health's overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
PureTech Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | (24,417,820) | |
| Geometric Mean | 57,917,824 | |
| Coefficient Of Variation | (449.98) | |
| Mean Deviation | 68,941,196 | |
| Median | (70,659,000) | |
| Standard Deviation | 109,875,460 | |
| Sample Variance | 12072.6T | |
| Range | 447.7M | |
| R-Value | 0.37 | |
| Mean Square Error | 11107.3T | |
| R-Squared | 0.14 | |
| Significance | 0.14 | |
| Slope | 8,067,064 | |
| Total Sum of Squares | 193161.9T |
PureTech Net Income From Continuing Ops History
About PureTech Health Financial Statements
PureTech Health stakeholders use historical fundamental indicators, such as PureTech Health's Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Although PureTech Health investors may analyze each financial statement separately, they are all interrelated. For example, changes in PureTech Health's assets and liabilities are reflected in the revenues and expenses on PureTech Health's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in PureTech Health PLC. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Income From Continuing Ops | 31.9 M | 33.5 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether PureTech Health PLC offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of PureTech Health's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Puretech Health Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Puretech Health Plc Stock:Check out the analysis of PureTech Health Correlation against competitors. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Will Biotechnology sector continue expanding? Could PureTech diversify its offerings? Factors like these will boost the valuation of PureTech Health. Anticipated expansion of PureTech directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every PureTech Health data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 0.615 | Earnings Share 1.7 | Revenue Per Share | Quarterly Revenue Growth 5.427 | Return On Assets |
The market value of PureTech Health PLC is measured differently than its book value, which is the value of PureTech that is recorded on the company's balance sheet. Investors also form their own opinion of PureTech Health's value that differs from its market value or its book value, called intrinsic value, which is PureTech Health's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because PureTech Health's market value can be influenced by many factors that don't directly affect PureTech Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between PureTech Health's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding PureTech Health should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, PureTech Health's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.